Outcomes of NUP98-rearranged hematological malignancy
| Tumor . | Age . | No. of patients . | Fusion partner . | Outcome . | Reference . | |
|---|---|---|---|---|---|---|
| Total . | Fusion . | |||||
| AML | Pediatric | 124 | 6 | NSD1 | 33.3% 4-y EFS and OS | 59 |
| AML | Pediatric | 246 | 15 | NSD1 | 13%, 52%, 81% 3-y EFS, OS, CIR, respectively | 32 |
| AML | Pediatric | 181 | 25 | NSD1 | 25% and 33% EFS with and without FLT3 alteration, respectively | 33 |
| AML | Pediatric | 98 | 18 | Mostly NSD1 (also KDM5A, TOP1) | 30% and 48% 5-y DFS and OS, respectively | 31 |
| AML | Pediatric | 385 | 10 | 9 NSD1, 1 KDM5A | 10% and 25% EFS and OS, respectively | 60 |
| AML | <3 y | 232 | 6 | KDM5A | 33.3%, 16.7%, 83.3% 3-y OS, EFS, CIR, respectively | 61 |
| AEL | Pediatric | 35 | 7 | 5 KDM5A, 2 NSD1 | ∼35% 5-y OS | 3 |
| AMKL | Pediatric | 87 | 5 | KDM5A | 35%, 25%, 62% 5-y OS, EFS, CIR, respectively | 62 |
| AMKL | Pediatric | 153 | 14 | KDM5A | 36%, 36%, 36% 4-y OS, EFS, CIR, respectively | 63 |
| FLT3-ITD+ AML | Pediatric | 44 | 8 | NSD1 | 4% complete response rate | 64 |
| AML | Pediatric | 238 | 12 | NSD1 | 31%, 8%, 83% 4-y OS, EFS, CIR, respectively | 34 |
| AML | Adult | 727 | 9 | NSD1 | 11%, 0%, 89% 4-y OS, EFS, CIR, respectively | 34 |
| AML | Pediatric | 2381 | 46 | KDM5A | 34%, 30%, 64% 4-y OS, EFS, RR, respectively | 55 |
| AML | Adult | 17 | 16 | HOXA9 | 4-mo median DFS, 8-mo median OS | 65 |
| AML | Adult | 493 | 11 | HOXA9 | 13.5-mo median OS, 6-mo median DFS | 66 |
| AML | Adult | 257 | 6 | NSD1 | 1.8-mo median EFS | 67 |
| AML | Younger adult, <60 y | 504 | 7 | NSD1 | 43% complete response rate | 68 |
| Tumor . | Age . | No. of patients . | Fusion partner . | Outcome . | Reference . | |
|---|---|---|---|---|---|---|
| Total . | Fusion . | |||||
| AML | Pediatric | 124 | 6 | NSD1 | 33.3% 4-y EFS and OS | 59 |
| AML | Pediatric | 246 | 15 | NSD1 | 13%, 52%, 81% 3-y EFS, OS, CIR, respectively | 32 |
| AML | Pediatric | 181 | 25 | NSD1 | 25% and 33% EFS with and without FLT3 alteration, respectively | 33 |
| AML | Pediatric | 98 | 18 | Mostly NSD1 (also KDM5A, TOP1) | 30% and 48% 5-y DFS and OS, respectively | 31 |
| AML | Pediatric | 385 | 10 | 9 NSD1, 1 KDM5A | 10% and 25% EFS and OS, respectively | 60 |
| AML | <3 y | 232 | 6 | KDM5A | 33.3%, 16.7%, 83.3% 3-y OS, EFS, CIR, respectively | 61 |
| AEL | Pediatric | 35 | 7 | 5 KDM5A, 2 NSD1 | ∼35% 5-y OS | 3 |
| AMKL | Pediatric | 87 | 5 | KDM5A | 35%, 25%, 62% 5-y OS, EFS, CIR, respectively | 62 |
| AMKL | Pediatric | 153 | 14 | KDM5A | 36%, 36%, 36% 4-y OS, EFS, CIR, respectively | 63 |
| FLT3-ITD+ AML | Pediatric | 44 | 8 | NSD1 | 4% complete response rate | 64 |
| AML | Pediatric | 238 | 12 | NSD1 | 31%, 8%, 83% 4-y OS, EFS, CIR, respectively | 34 |
| AML | Adult | 727 | 9 | NSD1 | 11%, 0%, 89% 4-y OS, EFS, CIR, respectively | 34 |
| AML | Pediatric | 2381 | 46 | KDM5A | 34%, 30%, 64% 4-y OS, EFS, RR, respectively | 55 |
| AML | Adult | 17 | 16 | HOXA9 | 4-mo median DFS, 8-mo median OS | 65 |
| AML | Adult | 493 | 11 | HOXA9 | 13.5-mo median OS, 6-mo median DFS | 66 |
| AML | Adult | 257 | 6 | NSD1 | 1.8-mo median EFS | 67 |
| AML | Younger adult, <60 y | 504 | 7 | NSD1 | 43% complete response rate | 68 |
AEL, acute erythroid leukemia; AMKL, acute megakaryoblastic leukemia; CIR, cumulative incidence of relapse; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; RR, relapse rate.